Piper Sandler Cuts MDxHealth (NASDAQ:MDXH) Price Target to $6.00

MDxHealth (NASDAQ:MDXH) had its price objective cut by Piper Sandler from $8.00 to $6.00 in a report published on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

Separately, Lake Street Capital assumed coverage on MDxHealth in a report on Thursday, October 31st. They set a “buy” rating and a $7.00 target price on the stock.

MDxHealth Stock Performance

MDXH opened at $2.03 on Thursday. The stock has a fifty day moving average of $2.27 and a 200-day moving average of $2.59. MDxHealth has a fifty-two week low of $1.95 and a fifty-two week high of $4.64. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 0.83.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings data on Wednesday, August 21st. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.05). The business had revenue of $22.16 million during the quarter, compared to analyst estimates of $20.66 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. On average, research analysts forecast that MDxHealth will post -1.13 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC boosted its holdings in shares of MDxHealth by 15.3% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock valued at $120,000 after purchasing an additional 7,656 shares in the last quarter. MVM Partners LLC lifted its position in shares of MDxHealth by 3.3% during the 3rd quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock worth $9,706,000 after buying an additional 150,000 shares during the last quarter. Finally, Perkins Capital Management Inc. boosted its stake in MDxHealth by 70.7% in the third quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock valued at $1,555,000 after buying an additional 309,500 shares in the last quarter.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.